Success Metrics

Clinical Success Rate
57.1%

Based on 4 completed trials

Completion Rate
57%(4/7)
Active Trials
0(0%)
Results Posted
75%(3 trials)
Terminated
3(38%)

Phase Distribution

Ph phase_2
2
25%
Ph phase_1
5
63%

Phase Distribution

5

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
5(71.4%)
Phase 2Efficacy & side effects
2(28.6%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

57.1%

4 of 7 finished

Non-Completion Rate

42.9%

3 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(4)
Terminated(3)
Other(1)

Detailed Status

Completed4
Terminated3
unknown1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
57.1%
Most Advanced
Phase 2

Trials by Phase

Phase 15 (71.4%)
Phase 22 (28.6%)

Trials by Status

completed450%
terminated338%
unknown113%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_1

Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC

NCT02039336
completedphase_1

PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors

NCT02022982
completedphase_1

MEK and MET Inhibition in Colorectal Cancer

NCT02510001
completedphase_2

MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1

NCT02096471
terminatedphase_1

Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer

NCT01347866
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT02039336Phase 1

Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC

Completed
NCT02022982Phase 1

PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors

Completed
NCT02510001Phase 1

MEK and MET Inhibition in Colorectal Cancer

Completed
NCT02096471Phase 2

MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1

Completed
NCT01347866Phase 1

Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer

Terminated
NCT02297802

A Single Patient IND for PD-0325901

Unknown
NCT00147550Phase 1

MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.

Terminated
NCT00174369Phase 2

MEK Inhibitor PD-325901 To Treat Advanced Non-Small Cell Lung Cancer

Terminated

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8